文献速递慢性肾脏病

改善慢性肾脏病患者的癌症诊疗:临床试验亟需变革

Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials.
PubMed 文献 · Kidney Int Rep · 2022-06-15

综述指出,抗癌药物多经肾脏排泄且治疗窗窄,但药物研发初期及注册前研究极少纳入重度肾功能不全(eGFR<30 ml/min或4G期CKD)或需肾脏替代治疗的终末期肾病患者,导致数据匮乏甚至被标注禁忌,阻碍这部分患者获得潜在获益药物。作者评估了将CKD患者排除于抗癌药物试验的科学依据,并提出一套综合策略以解决这一系统性问题。

要点

  • 抗癌药多经肾排泄且治疗窗窄,CKD患者安全有效剂量数据至关重要。
  • 药物研发初期仅纳入肾功能正常或轻度受损者,重度CKD及ESKD数据尤为有限。
  • 数据缺乏或安全顾虑可致药物被标注晚期肾病禁忌,阻碍患者获得潜在获益治疗。

核心结论

  • 将CKD患者系统排除于抗癌药物试验这一未解决问题,阻碍了为这些患者提供最佳临床照护,并引发包容性、多样性与公平性问题。
  • 随着人口老龄化,面临这些问题的CKD合并癌症患者数量不断增加。
  • 作者评估了将CKD患者排除于抗癌试验的科学依据,并提出一套综合策略以解决该问题。

研究设计与样本

  • 综述:评估将CKD患者排除于抗癌药物试验的科学依据,并提出综合策略。

主要发现

  • 抗癌药物通常治疗窗窄,并伴有潜在严重不良毒性。
  • 许多抗癌药物至少部分经肾脏排泄。
  • 药物研发初期临床研究仅纳入肾功能正常或仅轻度受损的患者。
  • 后续注册前研究仅纳入有限数量的更严重肾功能不全患者。
  • 重度肾功能不全(eGFR<30 ml/min或4G期CKD)或需肾脏替代治疗的ESKD患者数据在药物注册前尤为有限,且仅少数向美国食品药品监督管理局(FDA)提交的新药申请包含该人群数据。

关键数值与推荐

  • 重度肾功能不全定义为估算肾小球滤过率(eGFR)<30 ml/min或4G期CKD。
  • ESKD定义为需要肾脏替代治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemotherapeutic agents used to treat cancer generally have narrow therapeutic indices along with potentially serious adverse toxicities. Many cancer drugs are at least partially excreted through the kidney and, thus, the availability of accurate data on safe and effective dosing of these drugs in patients with chronic kidney disease (CKD) is essential to guide treatment decisions. Typically, during drug development, initial clinical studies only include patients with normal or only mildly impaired kidney function. In subsequent preregistration studies, a limited number of patients with more severe kidney dysfunction are included. Data obtained from patients with either severe kidney dysfunction (here defined as an estimated glomerular filtration rate [eGFR] < 30 ml/min or stage 4G CKD) or end-stage kidney disease (ESKD) requiring kidney replacement treatment are particularly limited before drug registration and only a minority of new drug applications to the US Food and Drug Administration (FDA) include data from this population. Unfortunately, limited data and/or other safety concerns may result in a manufacturer statement that the drug is contraindicated in patients with advanced kidney disease, which hinders access to potentially beneficial drugs for these patients. This systemic exclusion of patients with CKD from cancer drug trials remains an unsolved problem, which prevents provision of optimal clinical care for these patients, raises questions of inclusion, diversity, and equity. In addition, with the aging of the population, there are increasing numbers of patients with CKD and cancer who face these issues. In this review, we evaluate the scientific basis to exclude patients with CKD from cancer trials and propose a comprehensive strategy to address this problem.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sprangers B, Perazella MA, Lichtman SM, et al. Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. Kidney Int Rep. 2022. PMID: 36090489. doi:10.1016/j.ekir.2022.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。